Patents Issued in February 8, 2024
-
Publication number: 20240043542Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.Type: ApplicationFiled: October 11, 2023Publication date: February 8, 2024Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
-
Publication number: 20240043543Abstract: Combined therapy for a solid tumor, comprising an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17), and one or more chemotherapeutics, for example, gemcitabine, paclitaxel, or a combination thereof.Type: ApplicationFiled: November 19, 2021Publication date: February 8, 2024Inventors: Shohei KOIDE, Akiko KOIDE, Aleksandra FILIPOVIC, Eric ELENKO, Joseph BOLEN
-
Publication number: 20240043544Abstract: Disclosed herein is a polynucleotide comprising a human codon-optimized sequence encoding a polypeptide comprising EGFR806CAR. The codon-optimized sequence may be incorporated into a construct comprising an optimal-functioning promoter, spacer, intracellular signaling domain, transmembrane domain, selection marker, at least one self-cleaving peptides, and EFGRt, in order to optimize expression. This sequence may then be expressed in cells, such as T cells, for the treatment or inhibition of a cancer, such as glioblastoma, liquid tumors, or solid tumors.Type: ApplicationFiled: December 3, 2021Publication date: February 8, 2024Inventors: Michael C. Jensen, Jia Wei
-
Publication number: 20240043545Abstract: Provided herein are methods and compositions for treating an individual afflicted with an insulin-like growth factor 1 receptor (IGF1R) associated disorder using an antagonist of IGF1R signaling.Type: ApplicationFiled: May 25, 2023Publication date: February 8, 2024Inventors: Saba SILE, Jeffrey Wayne SHERMAN, Robert John HOLT, Theresa Anne PODREBARAC, Shayna Ravindran MELVANI
-
Publication number: 20240043546Abstract: Antibodies and compositions against IGF-1R and uses thereof are provided herein.Type: ApplicationFiled: August 3, 2023Publication date: February 8, 2024Inventors: Vahe Bedian, Peter Harwin, Tomas Kiselak, Angela She, Jonathan Violin, Yang Zhao
-
Publication number: 20240043547Abstract: The present invention relates to an antibody variable domain, which specifically binds to IL-31, to multispecific antibodies comprising one or two of said antibody variable domains and at least one further binding domain that specifically binds to a target different from IL-31. The present invention further relates to a nucleic acid or two nucleic acids encoding said antibody variable domain or said multispecific antibody, vector(s) comprising said nucleic acids or said nucleic acids, host cell(s) comprising said nucleic acid or said nucleic acids or said vector(s), and a method of producing said antibody variable domain or said multispecific antibody. Additionally, the present invention relates to pharmaceutical compositions comprising said antibody variable domain or said multispecific antibody and to methods of use thereof.Type: ApplicationFiled: December 23, 2021Publication date: February 8, 2024Inventors: Julia TIETZ, Tea GUNDE, Maria JOHANSSON, Stefan WARMUTH, Alexandre SIMONIN, Christian HESS
-
Publication number: 20240043548Abstract: The preparation and use of an anti-F SHR antibody and an antibody-drug conjugate thereof. Specifically, an antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment thereof contains a variable region and specifically binds to human follicle-stimulating hormone receptor FSEIR, and contains one, two, three, four, five or six CDRs with the following amino acid sequences shown in SEQ ID NOs: 6, 7, 8, 10, 11 and 12.Type: ApplicationFiled: November 18, 2021Publication date: February 8, 2024Applicant: CANWELL (GZ) BIOTECH LIMITEDInventors: Ninghui YU, Xuliang JIANG
-
Publication number: 20240043549Abstract: Anti-human CD40L antibodies engineered to lack the ability to activate platelets and methods for treating patients having a CD40L-associated disease.Type: ApplicationFiled: June 26, 2023Publication date: February 8, 2024Inventors: John M. Lincecum, Bingbing Jiang, Steven N. Perrin, Alan Gill, Cynthia A. Gill, Fernando G. Vieira
-
Publication number: 20240043550Abstract: Provided herein are de novo binding domain containing polypeptides (DBDpp) that specifically bind a target of interest. Nucleic acids encoding the DBDpp, and vectors and host cells containing the nucleic acids are also provided. Libraries of DBDpp, methods of producing and screening such libraries and the DBDpp identified from such libraries and screens are also encompassed. Methods of making and using the DBDpp are additionally provided. Such uses include, without limitation, affinity purification, and diagnostic and therapeutic applications.Type: ApplicationFiled: December 22, 2022Publication date: February 8, 2024Inventor: David William LAFLEUR
-
Publication number: 20240043551Abstract: Provided is an antibody or an antigen binding fragment thereof capable of specifically binding to Tumor necrosis factor receptor type 2, which comprises a VH, a VL or both, said VH comprises at least one HCDR, which comprises an amino acid sequence selected from the group consisting of the amino acid sequences as set forth in SEQ ID NO: 13, SEQ ID NO: 15 and SEQ ID NO: 17. The antibody or an antigen binding fragment thereof binds strongly and specifically to TNFR2.Type: ApplicationFiled: December 10, 2021Publication date: February 8, 2024Applicant: ADLAI NORTYE BIOPHARMA CO., LTD.Inventors: Yi ZHANG, Yonglin CHEN
-
Publication number: 20240043552Abstract: Methods for producing Fabs and IgG bi-specific antibodies comprising expressing nucleic acids encoding designed residues in the CH1/CL interface are provided. Also provided are Fabs and IgG bi-specific antibodies produced according to the provided methods as well as nucleic acids, vectors and host cells encoding the same.Type: ApplicationFiled: October 10, 2023Publication date: February 8, 2024Inventors: Stephen John Demarest, Karen Jean Froning, Brian Arthur Kuhlman, Andrew Philip Leaver-Fay
-
Publication number: 20240043553Abstract: The present invention relates to the treatment of subjects having previously untreated follicular lymphoma (FL). More specifically, the invention pertains to the treatment of subjects having previously untreated FL by administering a combination of mosunetuzumab and lenalidomide.Type: ApplicationFiled: June 21, 2023Publication date: February 8, 2024Inventors: Andrea KNAPP, Chi-Chung LI, Enkhtsetseg PUREV, Michael C. WEI
-
Publication number: 20240043554Abstract: The present disclosure provides methods for treating lupus nephritis in an individual that is greater than or equal to 12 years of age and less than 18 years of age. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody.Type: ApplicationFiled: September 12, 2023Publication date: February 8, 2024Applicants: Genentech, Inc., Hoffmann-La Roche Inc.Inventors: Justine Colette MALLER, Patricia LEHANE
-
Publication number: 20240043555Abstract: Provided herein is a method for treating or preventing a kidney disease or injury in a subject in need thereof, the method including administering to the subject a therapeutically effective amount of pharmaceutical composition including a CD24 inhibitor. Further provided is a method for inhibiting a damage associated molecular pattern (DAMP) in a subject, including administering to the subject a therapeutically effective amount of pharmaceutical composition including a CD24 inhibitor.Type: ApplicationFiled: August 3, 2023Publication date: February 8, 2024Inventors: Idit F. SCHWARTZ, Nadir ARBER, Doron SCHWARTZ, Lior YANKELSON
-
Publication number: 20240043556Abstract: Antibody drug conjugates (ADC's) that bind to 158P1D7 protein and variants thereof are described herein. 158P1D7 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in glioblastoma, lung cancer, bladder cancer, and breast cancer. Consequently, the ADC's of the invention provide a therapeutic composition for the treatment of cancer.Type: ApplicationFiled: March 10, 2023Publication date: February 8, 2024Applicants: AGENSYS, INC., SEAGEN INC.Inventors: Robert Kendall MORRISON, Zili AN, Karen Jane Meyrick MORRISON, Josh SNYDER, Xiao-Chi JIA
-
Publication number: 20240043557Abstract: It forms an object of the present invention a method to obtain monoclonal antibodies, or fragments or conjugates thereof, which bind with high affinity to a target protein which is a protein specifically expressed in local and metastatic tumors, preferably said target protein being Trop-2, wherein said method comprises: —making available an immunogenic material, wherein the immunogenic material is selected in the group comprising the target protein, fragments and conjugates thereof produced in different organisms, including tumor cells that naturally express the processed target protein and mammalian transformed and tumor cells, insect cells, yeast cells, bacterial cells that have been transfected with vectors that express the target protein and fragments thereof, also as fusion proteins with other sequences; —administering to a non-human animal one of said immunogenic material.Type: ApplicationFiled: December 21, 2021Publication date: February 8, 2024Inventors: Saverio ALBERTI, Marco TREROTOLA
-
Publication number: 20240043558Abstract: Provided are antibodies and antibody derivatives that bind to GPC3 and methods of using the same. The antibody or antibody derivative comprises a single domain antibody that binds to GPC3. The antibody derivative is a multispecific antibody that binds to GPC3 and an additional antigen, e.g., 4-1BB.Type: ApplicationFiled: October 20, 2023Publication date: February 8, 2024Inventors: Hassan ISSAFRAS, Wenfeng XU, Wei-Dong JIANG, Heungnam KIM
-
Publication number: 20240043559Abstract: Provided are antibodies and antibody derivatives that bind to GPC3 and methods of using the same. The antibody or antibody derivative comprises a single domain antibody that binds to GPC3.Type: ApplicationFiled: October 20, 2023Publication date: February 8, 2024Inventors: Hassan ISSAFRAS, Wenfeng XU, Wei-Dong JIANG, Heungnam KIM
-
Publication number: 20240043560Abstract: The present disclosure provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., prostate cancer or metastatic castration-resistant prostate cancer). The methods of the present disclosure comprise administering to a subject in need thereof a therapeutically effective amount of a bispecific antibody or antigen-binding fragment thereof that specifically binds prostate-specific membrane antigen (PSMA) and CD28 in combination with an antibody or antigen-binding fragment thereof that specifically binds to programmed death receptor-1 (PD-1).Type: ApplicationFiled: August 1, 2023Publication date: February 8, 2024Inventors: Elizabeth Miller, Sabina Sandigursky, Israel Lowy, Frank Seebach
-
Publication number: 20240043561Abstract: The present invention discloses humanized monoclonal antibodies that specifically bind to SLeA carbohydrate antigen with high specificity and selectivity, functional fragments of the humanized monoclonal antibodies such as scFv, and chimeric antigen receptors comprising the humanized monoclonal antibodies or the fragment thereof such as scFv. The invention further provides cells and compositions comprising the antibodies, fragments thereof or CARs as well as their use in diagnostics and treatment of cancer.Type: ApplicationFiled: November 23, 2021Publication date: February 8, 2024Inventors: Vered PADLER-KARAVANI, Ron AMON
-
Publication number: 20240043562Abstract: Novel methods for treating a condition or disorder associated with impaired neuromuscular transmission, such as MuSK myasthenia gravis (MuSK MG), in a subject are provided herein. Novel methods for treating a symptom associated with impaired neuromuscular transmission in a subject are also provided. The invention also provides multivalent binding agents for use in treating the same.Type: ApplicationFiled: September 5, 2019Publication date: February 8, 2024Inventors: Silvère Maria VAN DER MAAREL, Johannes Justus Gerard Maria VERSCHUUREN, Martina Gerardina Maria HUIJBERS, Jakob Jan PLOMP
-
Publication number: 20240043563Abstract: Disclosed are an antibody that can bind to human MASP-2, a preparation method therefor and an application thereof. The anti-human MASP-2 antibody of the present invention can specifically bind to human MASP-2, has good biological activity of inhibiting the cleavage of C4 and the generation of C3b, and can be applied in the treatment of MASP-2 related diseases, such as IgA nephropathy.Type: ApplicationFiled: October 13, 2023Publication date: February 8, 2024Inventors: Yipan WU, Wei DANG, Chenghai ZHANG, Lingqiao ZHU, Jinlin GUO, Yujing YUAN, Qiuling ZOU, Yang WANG, Shun HU
-
Publication number: 20240043564Abstract: The invention provides anti-BRDU antibodies and methods of using the same.Type: ApplicationFiled: May 1, 2023Publication date: February 8, 2024Applicant: Hoffmann-La Roche Inc.Inventors: Ulrich BRINKMANN, Guy GEORGES, Johannes AUER, Wilma LAU
-
Publication number: 20240043565Abstract: Provided herein are antibodies that selectively bind to PSMA and CD3, pharmaceutical compositions thereof, as well as methods of producing such antibodies.Type: ApplicationFiled: October 14, 2021Publication date: February 8, 2024Inventors: David CAMPBELL, Thomas R. DIRAIMONDO
-
Publication number: 20240043566Abstract: Provided are proteins comprising a PD-L1-binding moiety linked to a TGF?-binding moiety, IL-1-binding moiety, immunostimulatory polypeptides (e.g., soluble LAG3 or soluble CD4) or CD47-binding moiety, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same and the uses thereof.Type: ApplicationFiled: November 18, 2021Publication date: February 8, 2024Inventors: Xueming QIAN, Hongjun LI, Fei TENG, Huanhuan GUO, Yi GU
-
Publication number: 20240043567Abstract: A bispecific antibody is described. IL15 and IL15R? are respectively introduced into two chains of a first antibody of the bispecific antibody, and the high affinity of IL15 and IL15R? is utilized to form an IL15/IL15R? complex, thereby achieving the correct pairing of a light chain/heavy chain of the first antibody, and solving the problem of incorrectly matching light chains/heavy chains of bispecific antibodies. Meanwhile, the binding activity between the light chain/heavy chain of the first antibody may be further enhanced by adding one or more pairs of disulfide bonds between VH1 and VL1 and between IL15 and IL15R? by mutating the amino acid sequences of variable domains VH1, VL1, IL15 and IL15Ra of the first antibody to obtain correctly paired bispecific multifunctional antibodies targeting cytokines.Type: ApplicationFiled: May 19, 2021Publication date: February 8, 2024Inventor: Xiangdong QU
-
Publication number: 20240043568Abstract: The present disclosure relates to the development of a new tumor engager therapeutic drug and the use thereof. The therapeutic drug contains a bispecific antibody that binds to GPC3 and CD3, wherein the bispecific antibody contains a first binding domain that binds to GPC3 on the surface of a target cell and a second binding domain that binds to CD3 on the surface of a T cell. The bispecific antibody can inhibit tumor growth at a very low dose and effectively inhibit the growth of a transplanted tumor in an immune reconstitution mouse. A toxicological study conducted in cynomolgus monkeys also shows that animals have good tolerance to the bispecific antibody, and the efficacy and safety of the bispecific antibody are superior to those of similar antibodies.Type: ApplicationFiled: December 2, 2021Publication date: February 8, 2024Inventors: Bo CHEN, Gang XU, Qin SONG
-
Publication number: 20240043569Abstract: A method for producing high-purity derivatized starch which to used in the manufacture of paper and cardboard, a starch raw material is subjected to at least the following steps: purification, slurrying, derivatization, gelatinization, pH adjustment, wherein a slurry of the derivatized starch obtained after the slurrying and derivatization method steps carried out in any sequence is subjected to purification, preferably at an alkaline pH and that the purified and gelatinized derivatized starch obtained after gelatinization is mixed at least once with dilute acid as well as application.Type: ApplicationFiled: December 23, 2021Publication date: February 8, 2024Applicant: Mondi AGInventors: Tina OLKKONEN, Elisabeth SCHWAIGER, Roman STEINDL
-
Publication number: 20240043570Abstract: The present application provides for novel anhydride substituted starches and their use in personal and home care products. The natural based starches disclosed are useful for the replacement of chemical surfactants in personal and home care products. The starches demonstrate the unique ability to create and maintain desired properties in these products. The anhydride substituted starches are particularly useful in replicating the foaming properties of standard chemical surfactants.Type: ApplicationFiled: September 10, 2020Publication date: February 8, 2024Applicant: CARGILL, INCORPORATEDInventors: Stéphane BILTRESSE, Emmanuel Paul Jos Marie EVERAERT
-
Publication number: 20240043571Abstract: A bio-based starch mixed ester biodegradable and/or compostable composition includes a mixed starch mixed ester having a total degree of substitution of at least 1.0, wherein the ester substituents include a mixture of (a) acetate and (b) one or more C10 to C24 ester residues, wherein the degree of substitution of (a) is greater than (b). A method of preparing a bio-based starch mixed ester biodegradable and/or compostable composition having a degree of substation of at least 1.0 includes reacting starch with a mixed acid anhydride in the presence of an esterification catalyst to form a starch mixed ester composition wherein the mixed acid anhydride is formed from (a) an acid anhydride and (b) a carboxylic acid having 10 to 24 carbon atoms.Type: ApplicationFiled: July 28, 2023Publication date: February 8, 2024Inventors: Yuma Hiromoto, Yuri Sakakibara, Erika Kurachi
-
Publication number: 20240043572Abstract: Articles of manufacture formed from starch ester biodegradable and/or compostable compositions and blends of starch ester biodegradable and/or compostable compositions with biodegradable and/or compostable polymer compositions. The articles of manufacture may include but are not limited to inks, paints, compost bag, laminate bags, agricultural films, binder for earthenware, landscape piles or spikes, bottles, strands, sheets, films, packaging materials, pipes, tubes, lids, cups, rods, laminated films, sacks, bags, cutlery, pharmaceutical capsules, foams, granulates and powders.Type: ApplicationFiled: July 28, 2023Publication date: February 8, 2024Inventors: Yuma Hiromoto, Yuri Sakakibara, Erika Kurachi
-
Publication number: 20240043573Abstract: The present invention provides a polymerizable unsaturated group-containing cyclodextrin derivative, which can be efficiently prepared with a higher yield and a higher purity, and which can be mass-produced. The polymerizable unsaturated group-containing cyclodextrin derivative is represented by the following general formula (1). (In the formula, R1 represents any one of (A) the following general formula (2) —R3—NH—R4 ??(2) (R3 is an alkylene group having 3 to 20 carbon atoms, may be linear or branched, and may have a substituent. R4 represents a (meth)acryloyl group or a vinyl group-containing alkyl group having 3 to 50 carbon atoms.) (B) the following general formula (3) —R5—NHCONH—R6 ??(3) (R5 is an alkylene group having 3 to 20 carbon atoms, may be linear or branched, and may have a substituent.Type: ApplicationFiled: July 21, 2021Publication date: February 8, 2024Applicant: KYOEISHA CHEMICAL CO., LTD.Inventors: Yuya TAKAHASHI, Bunsho KURE, Tsuyoshi YAMAGUCHI, Naomi TAKENAKA, Yoshinori TAKASHIMA, Akira HARADA, Motofumi OSAKI
-
Publication number: 20240043574Abstract: A polymer of hyaluronic acid modified by the grafting thereto of at least one of the functions —SO3? and aromatic rings may be used as dopant for a polymer formed from one or monomers chosen from EDOT, ProDOT, and derivatives thereof. An aqueous suspension, or ink, and materials, in particular hydrogels, based on at least one PEDOT and/or PProDOT polymer may be doped by at least one such modified hyaluronic acid polymer. Such modified hyaluronic acid polymers may be used in bioelectronic or biosensor devices.Type: ApplicationFiled: December 16, 2021Publication date: February 8, 2024Applicants: COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE GRENOBLE ALPESInventors: Maxime LEPRINCE, Rachel AUZELY, Isabelle TEXIER-NOGUES
-
Publication number: 20240043575Abstract: An ultraviolet curable resin composition containing: a monomer and/or an oligomer having a polymerizable unsaturated double bond; a photopolymerization initiator; and an acid having an acid dissociation constant (pKa1) in pure water of 4.0 or less.Type: ApplicationFiled: November 12, 2021Publication date: February 8, 2024Applicant: Denka Company LimitedInventors: Yuki KIMOTO, Yasunori HAYASHI, Mizuki HASUMI
-
Publication number: 20240043576Abstract: Disclosed is a Ziegler-Natta catalyst composition comprising one or more Ziegler-Natta procatalyst compositions which comprise magnesium, titanium, a halogen, one or more internal electron donors; one or more aluminum containing cocatalysts; optionally one or more stereo-selectivity control agents (SCA); and one or more activity limiting agents (ALA) comprising one or more alkyl-, cycloalkyl- or aryl carbonates and derivatives. Such a Ziegler-Natta catalyst composition exhibits self-limiting catalyst activity in olefin polymerization, particularly propylene polymerization.Type: ApplicationFiled: August 8, 2022Publication date: February 8, 2024Inventors: Lei Zhang, Gapgoung Kong, Guangxue Xu, Cyrus C. Y. Lee, Chih-Jian Chen
-
Publication number: 20240043577Abstract: Methods for preparing a metallocene-based catalyst composition that can impact the long chain branching of ethylene homopolymers and copolymers produced using the catalyst composition are described. The catalyst composition can be prepared by contacting a metallocene compound, a hydrocarbon solvent, and a first organoaluminum compound for a first period of time to form a metallocene solution, and then contacting the metallocene solution with an activator-support and a second organoaluminum compound for a second period of time to form the catalyst composition.Type: ApplicationFiled: October 18, 2023Publication date: February 8, 2024Inventors: Qing Yang, Max P. McDaniel, Tony R. Crain
-
Publication number: 20240043578Abstract: A pre-catalyst composition comprising: a) a silica support comprising silica wherein an amount of silica is in a range of from about 70 wt. % to about 95 wt. % based upon a total weight of the silica support; b) a titanium-containing compound wherein an amount of titanium is in a range of from about 0.1 wt. % to about 10 wt. % based upon the total weight of the silica support; c) a chromium-containing compound wherein an amount of chromium is in a range of from about 0.1 wt. % to about 10 wt. % based upon the total weight of the silica support; d) a surfactant wherein the surfactant comprises a non-ionic surfactant, a cationic surfactant, or a combination thereof; e) a carboxylate wherein the carboxylate comprises a multi carboxylate, an alpha-hydroxy carboxylate, or a combination thereof; and f) a solvent.Type: ApplicationFiled: October 18, 2023Publication date: February 8, 2024Inventors: Max P. MCDANIEL, Kathy S. CLEAR, William C. ELLIS, Deloris R. GAGAN
-
APPARATUS AND METHOD FOR REMOVING VOC FROM POLYPROPYLENE AND REDUCING ODOR LEVEL BY STEAMING PROCESS
Publication number: 20240043579Abstract: An apparatus for removing VOC in polypropylene by steaming process includes: a cyclone separator, used for separating polypropylene particles and entraining gas from an upstream pneumatic system; a preheating tower, communicating with a discharge hole of the cyclone separator, a first steam inlet being provided on a tower body of the preheating tower, and a tail gas outlet being provided on top of the preheating tower; and a devolatilization tower, communicating with a discharge hole of the preheating tower, a second steam inlet being provided on a tower body of the devolatilization tower, a steam outlet being provided on top of the tower, and the steam outlet being communicating with the first steam inlet.Type: ApplicationFiled: February 28, 2022Publication date: February 8, 2024Inventors: Xu ZHAO, Yan GAO, Yonggong LING, Tao ZHOU, Yongning QIU, Shaohua YANG, Chao MI, Qingsheng DONG, Fan ZHANG, Xinxing WANG, Kaixuan MA, Xiaoling XIE -
Publication number: 20240043580Abstract: Polyethylene composition has a density of 949-955 kg/m 3 and a melt index MI2 between 15 and 40 g/10 min, and comprises a low molecular weight fraction (A) and a high molecular weight fraction (B), wherein the amount of (A) is 52-58 wt % based on the weight of (A)+(B), and the melt index MI2 of (A) is 200-600 g/10 min. Injection moulded articles, preferably caps or closures, made from the composition are also described.Type: ApplicationFiled: December 16, 2021Publication date: February 8, 2024Inventors: Pascale GODON, Luc Marie Ghislain DHEUR
-
Publication number: 20240043581Abstract: A process for producing an olefin polymer employs a gas phase polymerization reactor in fluid communication with a vent column and a product discharge system. The discharge system can include first and second pairs of lock hoppers, where each pair includes an upstream lock hopper connected by a valve to the reactor and a downstream lock hopper connected by a valve to the upstream lock hopper and by a further valve to a product recovery system, and where a first cross-tie can be provided between the upstream lock hoppers of the first and second pairs of lock hoppers and a second cross-tie can be provided between the downstream lock hoppers of the first and second pairs of lock hoppers. Upon reaching the vent column's maximum removal capacity, additional gas can be removed from the reactor by reducing the frequency of opening the second cross-tie between the downstream lock hoppers.Type: ApplicationFiled: February 25, 2022Publication date: February 8, 2024Inventors: Nathaniel B. GUY, Stacy N. OLALEYE, Michael D. LUCAS, Handel D. BENNETT, David T. LAKIN, Benjamin J. OHRAN, Aaron C. MCGINNIS
-
Publication number: 20240043582Abstract: Provided is a resin composition for obtaining a resin molded product which simultaneously exhibits three excellent effects of flame retardance, heat resistance, and mechanical strength. One aspect of the resin composition of the present invention is obtained by radically polymerizing a monomer mixture containing methyl methacrylate, a phosphorus atom-containing compound (C), and a phosphine compound (D), where the phosphorus atom-containing compound (C) comprises at least one selected from a phosphoric acid ester compound and a phosphonic acid ester compound, and the phosphine compound (D) is represented by Formula (I). [In Formula (I), R1, R2, and R3 each independently represent an aromatic hydrocarbon group having 6 to 12 carbon atoms, or the like.Type: ApplicationFiled: August 8, 2023Publication date: February 8, 2024Applicant: Mitsubishi Chemical CorporationInventors: Manabu Isomura, Shouta Ichise
-
Publication number: 20240043583Abstract: A rubber composition is based on at least one elastomer matrix predominantly comprising a highly saturated diene elastomer, carbon black and an aliphatic diacid dialkyl ester, the highly saturated diene elastomer being a copolymer of ethylene and a 1,3-diene in which the ethylene units represent at least 50 mol % of the monomer units of the copolymer.Type: ApplicationFiled: November 29, 2021Publication date: February 8, 2024Inventors: JOSE-CARLOS ARAUJO DA SILVA, BENJAMIN GORNARD, FRANCOIS LALLET
-
Publication number: 20240043584Abstract: Disclosed is a process for producing a propylene polymer composition comprising a long chain branched propylene polymer, wherein the propylene polymer composition has a) a melt flow rate MFR2 (230° C., 2.16 kg) of 0.8 to 6.0 g/10 min b) a xylene hot insolubles (XHU) fraction in an amount of not more than 0.80 wt %, based on the total weight amount of the propylene polymer composition, c) a melting temperature Tm of at least 160.0° C., d) a F30 melt strength of from 5.0 to less than 30.0 cN, and e) a heat distortion temperature (HDT) of at least 108° C., the process comprising reactive modification of a propylene polymer in the presence of a peroxide. Also disclosed is an article comprising said propylene polymer composition.Type: ApplicationFiled: October 12, 2023Publication date: February 8, 2024Applicant: BOREALIS AGInventors: Jingbo WANG, Markus GAHLEITNER, Klaus BERNREITNER, Katja Ellen KLIMKE, Friedrich BERGER
-
Publication number: 20240043585Abstract: Binder compositions for fiberglass are disclosed, comprising a polycarboxylic acid such as polyacrylic acid and a crosslinking agent. The crosslinking agent comprises a polyhydroxy component formed from a reaction of an epoxidized plant oil with an amine and optionally with a phenolic compound. The molar ratio of the amine to the epoxidized plant oil at the beginning of said reaction may be greater than 1:1. Methods of making the binders and fiber-containing composites made with said binders are also described.Type: ApplicationFiled: August 3, 2022Publication date: February 8, 2024Inventors: Kiarash Alavi, Ameya Natu, Uranchimeg Lester, James Cottier, Jawed Asrar
-
Publication number: 20240043586Abstract: The present invention relates to a rubber composition comprising rubber, a first filler comprising a carbon-based inorganic compound, wherein the carbon-based inorganic compound comprises interconnected crystalline carbon nanofilaments and a second filler comprising silica. Said rubber composition can be used for coating wires or cords which are used for reinforcing rubber products such as tires. It can be used in tires such as in carcass plies, belt plies, ply strips and overlay plies. The present invention further relates to a pneumatic tire comprising said rubber composition.Type: ApplicationFiled: July 27, 2022Publication date: February 8, 2024Inventors: Adrian Osvaldo Balaguer Pino, Carolin Anna Welter, Julia Martine Francoise Claudine Tahon, Dawn Michelle Johnson
-
Publication number: 20240043587Abstract: The present invention is directed to a rubber composition for a truck tire, the rubber composition comprising 70 phr to 95 phr of polyisoprene, and 5 phr to 30 phr of a solution polymerized styrene butadiene rubber having a glass transition temperature of less than ?40° C. which is functionalized for the coupling to silica. Furthermore, the rubber composition comprises 40 phr to 80 phr of a filler comprising predominantly silica. Moreover, the present invention is directed to a truck tire comprising the rubber composition and to a truck comprising such a tire.Type: ApplicationFiled: July 28, 2022Publication date: February 8, 2024Inventors: Jean-Noel Marsat, Marine Sophie Francoise Wassen, Manuela Pompei, Karmena Izabela Anyfantaki
-
Publication number: 20240043588Abstract: An olefinic polymer and a method for preparing the olefinic polymer are disclosed. The olefinic polymer has excellent melt strength, and thus has excellent bubble stability during blown film molding. The olefinic polymer has (1) a density of 0.9 to 0.95 g/cm3; (2) a melt index (I2.16) of 0.1 to 5.0 g/10 min as measured with a load of 2.16 kg at 190° C.; (3) a ratio between a melt index (I21.6) measured with a load of 21.6 kg and a melt index (I2.16) measured with a load of 2.16 kg at 190° C. (melt flow ratio; MFR) of 20 or more; (4) a melt tension of 55 mN or more at a velocity at break of 350 mm/s; and (5) a maximum velocity at break of 550 mm/s or more.Type: ApplicationFiled: December 2, 2021Publication date: February 8, 2024Applicant: HANWHA SOLUTIONS CORPORATIONInventors: Jisong JO, Jeong Hyun PARK, Sung Dong KIM, Munhee LEE, Ui Gap JOUNG
-
Publication number: 20240043589Abstract: Propylene-ethylene copolymers are provided that exhibit superior tensile strength and mechanical properties due to their specific propylene and ethylene content, triad tacticity, viscosity, and crystallinity. Moreover, we have discovered that certain processing conditions, such as polymerization temperature and external donor to catalyst ratios, can facilitate the production of the high tensile strength propylene-ethylene copolymers described herein. Furthermore, the high tensile strength propylene-ethylene copolymers may be used to produce a variety of hot melt adhesives, such as those for hygiene applications, woodworking applications, lamination applications, and packaging applications, which exhibit unique and superior mechanical properties.Type: ApplicationFiled: July 26, 2022Publication date: February 8, 2024Inventors: Jianning Liu, Marc Stacey Somers, Bennett Haines Novak, Raymond Prescott Cottle, Bee Kim Liew, Andrea Gail Hagood, Terri Roxanne Carvagno
-
Publication number: 20240043590Abstract: Visbroken and monomodal random polypropylene copolymers are disclosed that have excellent impact resistance properties. Because the polymers are monomodal, the polymers also have excellent optical characteristics. In order to produce the polymers, a high molecular weight and low melt flow rate polypropylene polymer is combined with a visbreaking agent under molten conditions that has been found to dramatically improve impact resistance.Type: ApplicationFiled: October 1, 2021Publication date: February 8, 2024Inventors: Zhiru MA, John K. KAARTO
-
Publication number: 20240043591Abstract: A process can be used for manufacturing an acrylic copolymer having increased heat resistance, high transparency, and improved adhesion to metal surfaces. The process involves polymerizing a monomer mixture, optional heating of the copolymer mixture, and removing volatile components from the copolymer mixture by degassing. Moulding compositions containing this copolymer are highly suitable for manufacturing optical elements for optoelectronic devices containing acrylic and metallic or ceramic parts.Type: ApplicationFiled: December 8, 2021Publication date: February 8, 2024Applicant: Röhm GmbHInventors: Rüdiger Carloff, Werner Arnold, Gerald Dietrich
